Access cutting-edge her2+ cancer treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access her2+ cancer specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related her2+ cancer treatment provided free
The purpose of this study to see how the brain absorbs, distributes, and gets rid of tucatinib in people who have HER2+ cancers (breast cancer, NSCLC, CRC, or GEC) that have spread to the brain, and to learn more about how cancer cells develop resistance to treatment. The researchers will do research tests to look for genetic differences between HER2+ breast cancer that has spread to the brain and progressed during treatment with tucatinib and cancers that are being treated with tucatinib for th
Sponsor: Memorial Sloan Kettering Cancer Center
Check if you qualify for this her2+ cancer clinical trial in New York, NY
If you're searching for her2+ cancer treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced her2+ cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.